Evidence map›Paper›PMID 36718646›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.

Cody P Doolan, Babak Sahragard, Jenine Leal, Anuj Sharma, Joseph Kim, Eldon Spackman, Aidan Hollis, Dylan R Pillai

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled TrialPragmatic Clinical Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03857464 (C. Difficile Near-patient Testing Versus Centralized Laboratory Testing), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03857464 nacompletednot on this map

C. Difficile Near-patient Testing Versus Centralized Laboratory Testing: a Cluster Randomized Trial

TypeinterventionalSponsorUniversity of CalgaryRan2019 to 2020Enrolled3,816ConditionsClostridium DifficileArmsNear Patient Testing, SOP for C. difficile diagnostics
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Cody P DoolanDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Alberta, Canada.
Babak SahragardDepartment of Economics, Simon Fraser University, Burnaby, British Columbia, Canada.
Jenine LealInfection Prevention and Control, Alberta Health Services, Calgary, Alberta, Canada.
Anuj SharmaEphicacy Canada Inc., Toronto, Ontario, Canada.
Joseph KimInfection Prevention and Control, Alberta Health Services, Calgary, Alberta, Canada.
Eldon SpackmanDepartment of Community Health Sciences, University of Calgary, Alberta, Canada.
Aidan HollisDepartment of Economics, University of Calgary, Calgary, Alberta, Canada.
Dylan R PillaiDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
University of Calgary · CAAlberta Health Services · CASimon Fraser University · CA

Funding

CIHRCIHR PJT 156251
6 · The paper itself

Abstract

backgroundManagement of suspected Clostridioides difficile infection (CDI) in the hospital setting typically results in patient isolation, laboratory testing, infection control, and presumptive treatment. We investigated whether implementation of rapid near-patient testing (NPT) reduced patient isolation time, hospital length of stay (LOS), antibiotic usage, and cost.

methodsA 2-period pragmatic cluster randomized crossover trial was conducted. Thirty-nine wards were randomized into 2 study arms. The primary outcome measure was effect of NPT on patient isolation time using a mixed-effects generalized linear regression model. Secondary outcomes examined were hospital LOS and antibiotic therapy based on a negative binomial regression model. Natural experiment (NE), intention-to-treat (ITT), and per-protocol (PP) analyses were conducted.

resultsDuring the entire study period, a total of 656 patients received NPT for CDI and 1667 received standard-of-care testing. For the primary outcome, a significant decrease of patient isolation time with NPT was observed (NE, 9.4 hours [P < .01]; ITT, 2.3 hours [P < .05]; PP, 6.7 hours [P < .1]). A significant reduction in hospital LOS was observed with NPT for short stay (NE, 47.4% [P < .01]; ITT, 18.4% [P < .01]; PP, 34.2% [P < .01]). Each additional hour delay for a negative result increased metronidazole use (24 defined daily doses per 1000 patients; P < .05) and non-CDI-treating antibiotics by 70.13 mg (P < .01). NPT was found to save 25.48 US dollars per patient when including test cost to the laboratory and patient isolation in the hospital.

conclusionsThis pragmatic cluster randomized crossover trial demonstrated that implementation of CDI NPT can contribute to significant reductions in isolation time, hospital LOS, antibiotic usage, and healthcare cost. Clinical Trials Registration. NCT03857464.

Indexed as

Clostridioides difficileClostridium InfectionsAnti-Bacterial AgentsClostridioidesCross-Over StudiesHumansMetronidazoleAnti-Bacterial AgentsMetronidazoleClostridium difficilecostdiagnosticsnear patient testingoutcomes

Identifiers

PMID36718646
PMCPMC10249988
OpenAlexW4318670792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.